Tenofovir

• CAT Number: A000668
• CAS Number: 147127-20-6
• Molecular Formula: C9H14N5O4P
• Molecular Weight: 287.20
• Purity: ≥95%
• Synonyms: 147127-20-6; Apropovir; PMPA; (R)-9-(2-Phosphonomethoxypropyl)adenine; PMPA gel
• Target: Reverse Transcriptase
• Solubility: Soluble in DMSO > 10 mM
• Storage: -20°C
• IUPAC Name: [(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid
• InChI: InChI=1S/C9H14N5O4P/c1-6(18-5-19(15,16)17)2-14-4-13-7-8(10)11-3-12-9(7)14/h3-4,6H,2,5H2,1H3,(H2,10,11,12)(H2,15,16,17)/t6-/m1/s1
• InChIKey: SGOIRFVFHAKUTI-ZCFIWIBFSA-N
• SMILES: C[C@H](CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O

Tenofovir（Cat No.:A000668）is a nucleotide reverse transcriptase inhibitor (NRTI) widely used in the treatment of HIV-1 and chronic hepatitis B infections. It works by inhibiting reverse transcriptase, incorporating into viral DNA, and causing chain termination, thereby halting viral replication. Tenofovir is available in two forms: Tenofovir disoproxil fumarate (TDF) and Tenofovir alafenamide (TAF), with TAF offering improved safety for kidneys and bones. Its high efficacy and low resistance profile make it a cornerstone of antiretroviral therapy. Tenofovir is also extensively studied for its role in pre-exposure prophylaxis (PrEP) and antiviral drug development.